Regenicin, Inc.

OTC: RGIN · Healthcare · Biotechnology

PublicHQ Little Falls, NJCIK 0001412659Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 31

v0.1 · 5/100 weight · pillars only

↑ listing tenure, Altman-Z · ↓ balance-sheet leverage, return on assets

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$877.1k

Employees

Market cap

$15.3k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$877.1k-$877.1k2021

Operating income-$842.4k-$842.4k2021

Total assets$4.6k$4.6k2021

Liabilities$4.4M$4.4M2014

Equity-$5.2M-$5.2M2021

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Regenicin, Inc. earned -$877.1k in FY2021 net income.

Peers · Healthcare

Aeolus Pharmaceuticals, Inc.——Halo Collective Inc.——AREV Life Sciences Global Corp——Body and Mind Inc.——

Key facts

CEORandall E. McCoy

SectorHealthcare

IndustryBiotechnology

HeadquartersLittle Falls, NJ

ExchangeOTC: RGIN

Employees3

IPO date2009-11-16

Latest filings

8-K2024-12-23 8-K2024-11-12 8-K2024-11-06 8-K2023-09-14 10-Q2023-05-15 10-Q2023-02-13 10-K2023-01-13 10-Q2022-08-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.